« Return to News | CROs/Service Providers

Omnicare re-brands as Theorem Clinical Research

Thursday, June 16, 2011 10:29 AM

CRO Omnicare Clinical Research, based in King of Prussia, Penn., has re-branded the company under the name Theorem Clinical Research. The brand launch marks the final step in the CRO's separation from its former parent company in a deal that was finalized this spring.

Nautic Partners, a private equity firm based in Providence, R.I., acquired the CRO in April. The deal marked the official the separation of Omnicare Clinical Research from former parent company Omnicare.

It also, the company said, accomplished its most visible step in achieving its long-identified goal: to stand on its own and deliver results the way that clients need.

Under its new name, Theorem Clinical Research will continue to provide clinical trial management, with a continued focus on its core early phase, phase II/III and late phase, and its specialized business units in pharmaceutics, medical device and technical services (biometrics and clinical data management).

"This is 25 years in the making," said Dr. James Pusey, president and CEO of Theorem Clinical Research. “We are now in the driver's seat of our own company.”

Over the last five years the company has completed over 1,500 studies worldwide with more than 337,000 participating patients.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.